OBJECTIVE: To examine whether tumor-selective infiltration, activation, and cytotoxic activity of tumor infiltrating T lymphocytes (TIL) can be demonstrated in situ in colorectal cancer samples. SUMMARY BACKGROUND DATA: Recent studies indicated a correlation between the presence of TIL and an improved prognosis in colorectal cancer. However, tumor-selective activation and cytotoxic activity of CD8 TIL in situ in colorectal cancer patients have not yet been examined. METHODS: Tumor samples from 49 patients and corresponding normal mucosa samples from 23 patients with colorectal cancer (UICC stages II-IV) were examined for TIL. Two-color fluorescence immunohistochemistry and multicolor flowcytometric (FACS) analysis were used for quantification of CD8 T cells and measurement of their activation status (CD69-expression) and cytotoxic activity (CD107a-expression) in situ. Presence of tumor antigen-reactive T cells in tumor, blood, and bone marrow was evaluated by IFN-gamma Elispot analysis. RESULTS: While absolute numbers of CD8 T cells were similar, CD4 T helper cells were significantly increased in tumor tissue compared with normal mucosa. There was a significantly higher proportion of activated and cytotoxically active CD8 TIL in colorectal cancer compared with normal mucosa. Increased activation, cytotoxic activity, and functional reactivity of TIL were correlated with the presence of functional tumor antigen-reactive T cells in the blood and bone marrow. The proportion of activated TIL decreased significantly with higher tumor stage. CONCLUSIONS: Tumor-selective activation and cytotoxic activity of CD8 TIL and tumor-selective migration of CD4 T helper cells were demonstrated in colorectal cancer for the first time. Our data support the immunogenicity of colorectal cancer and suggest clinical significance of tumor-specific immune responses.
OBJECTIVE: To examine whether tumor-selective infiltration, activation, and cytotoxic activity of tumor infiltrating T lymphocytes (TIL) can be demonstrated in situ in colorectal cancer samples. SUMMARY BACKGROUND DATA: Recent studies indicated a correlation between the presence of TIL and an improved prognosis in colorectal cancer. However, tumor-selective activation and cytotoxic activity of CD8 TIL in situ in colorectal cancerpatients have not yet been examined. METHODS:Tumor samples from 49 patients and corresponding normal mucosa samples from 23 patients with colorectal cancer (UICC stages II-IV) were examined for TIL. Two-color fluorescence immunohistochemistry and multicolor flowcytometric (FACS) analysis were used for quantification of CD8 T cells and measurement of their activation status (CD69-expression) and cytotoxic activity (CD107a-expression) in situ. Presence of tumor antigen-reactive T cells in tumor, blood, and bone marrow was evaluated by IFN-gamma Elispot analysis. RESULTS: While absolute numbers of CD8 T cells were similar, CD4 T helper cells were significantly increased in tumor tissue compared with normal mucosa. There was a significantly higher proportion of activated and cytotoxically active CD8 TIL in colorectal cancer compared with normal mucosa. Increased activation, cytotoxic activity, and functional reactivity of TIL were correlated with the presence of functional tumor antigen-reactive T cells in the blood and bone marrow. The proportion of activated TIL decreased significantly with higher tumor stage. CONCLUSIONS:Tumor-selective activation and cytotoxic activity of CD8 TIL and tumor-selective migration of CD4 T helper cells were demonstrated in colorectal cancer for the first time. Our data support the immunogenicity of colorectal cancer and suggest clinical significance of tumor-specific immune responses.
Authors: Feng Guang Gao; Vithagna Khammanivong; Wen Jun Liu; Graham R Leggatt; Ian H Frazer; Germain J P Fernando Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: D Nagorsen; U Keilholz; L Rivoltini; A Schmittel; A Letsch; A M Asemissen; G Berger; H J Buhr; E Thiel; C Scheibenbogen Journal: Cancer Res Date: 2000-09-01 Impact factor: 12.701
Authors: Lianhua Bai; Philipp Beckhove; Markus Feuerer; Viktor Umansky; Carmen Choi; Florian Schütz Erich-Franz Solomayer; Ingo J Diel; Volker Schirrmacher Journal: Int J Cancer Date: 2003-01-01 Impact factor: 7.396
Authors: M Feuerer; P Beckhove; L Bai; E F Solomayer; G Bastert; I J Diel; C Pedain; M Oberniedermayr; V Schirrmacher; V Umansky Journal: Nat Med Date: 2001-04 Impact factor: 53.440
Authors: Axel C P Diederichsen; J v B Hjelmborg; Per B Christensen; Jesper Zeuthen; Claus Fenger Journal: Cancer Immunol Immunother Date: 2003-04-15 Impact factor: 6.968
Authors: Anand G Menon; Connie M Janssen-van Rhijn; Hans Morreau; Hein Putter; Rob A E M Tollenaar; Cornelis J H van de Velde; Gert Jan Fleuren; Peter J K Kuppen Journal: Lab Invest Date: 2004-04 Impact factor: 5.662
Authors: Valerie Rubio; Tor B Stuge; Naileshni Singh; Michael R Betts; Jeffrey S Weber; Mario Roederer; Peter P Lee Journal: Nat Med Date: 2003-10-05 Impact factor: 53.440
Authors: Jeffrey Chou; Lilien N Voong; Christie L Mortales; Andrea M H Towlerton; Seth M Pollack; Xiaoji Chen; Cassian Yee; Paul F Robbins; Edus H Warren Journal: J Immunother Date: 2012 Feb-Mar Impact factor: 4.456
Authors: Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove Journal: J Clin Invest Date: 2014-12-22 Impact factor: 14.808
Authors: A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec Journal: Br J Cancer Date: 2009-09-15 Impact factor: 7.640
Authors: Dalibor Antolovic; Luis Galindo; Anina Carstens; Nuh Rahbari; Markus W Büchler; Jürgen Weitz; Moritz Koch Journal: BMC Biotechnol Date: 2010-04-28 Impact factor: 2.563
Authors: Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken Journal: BMC Immunol Date: 2010-04-12 Impact factor: 3.615